IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: Gene expression analysis employing all reported protein-protein interactions

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 116-120

  Yamaguchi, Ken D ^a   Ruderman, Daniel L ^b   Croze, Ed ^a   Wagner, T Charis ^b   Velichko, Sharlene ^a   Reder, Anthony T ^c   Salamon, Hugh ^b  

^a BAYER CORPORATION   (United States)

^b BAYER AG   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Computational biology; Gene expression profiling; Interferon beta; Pathway analysis; Relapsing remitting multiple sclerosis; Statistics

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 4; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECURRENT DISEASE; REMISSION;

COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYASTHENIA GRAVIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TIME FACTORS;

EID: 42049094003     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.12.007     Document Type: Article

References (18)

1. Altman D.G. Practical Statistics for Medical Research (1999), CRC Press, Boca Raton
2. Bild A., and Febbo P.G. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15278-15279
3. Cope L.M., Irizarry R.A., Jafee H., Wu Z., and Speed T.P. A benchmark for Affymetrix GeneChip expression values. Bioinformatics 20 (2004) 323-331
4. Croze E., Salamon H., Velichko S., Wagner T.C., Kraetzschmar J., Stuerzebecher C.S., and Reder A.T. Betaseron in multiple sclerosis: peripheral blood mononuclear cell gene expression profiles on multiple sclerosis patients suggest multiple mechanisms of action and potential biomarkers. Mult. Scler. 10 (2004) S215
5. Fisher R.A. Statistical Methods for Research Workers. 6th Ed. (1936), Oliver & Boyd, London
6. Gentleman R.C., Cary V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gauiter L., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5 (2004) R80
7. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., and Haines J.L. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39 (2007) 1083-1091
8. Harris R., and Ukaejiofo E.O. Tissue typing using a routine one-step lymphocyte separation technique. Br. J. Haematol. 18 (1970) 229-235
9. The IFN beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
10. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007) 851-862
11. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs H., and Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31 (2003) e15
12. Kurzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
13. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallström E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., and Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39 (2007) 1108-1113
14. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
15. Miklos G.L., and Maleszka R. Microarray reality checks in the context of a complex disease. Nat. Biotechnol. 22 (2004) 615-621
16. Velichko S., Wagner T.C., Yamaguchi K., Salamon H., Reder T., Stuerzebecher C.S., Hilpert J., Beekman J., Kowal K., Schwenke S., and Croze E. Betaseron pharmacogenomics studies: gene expression profiling in healthy individuals and relapsing-remitting multiple sclerosis patients after a single dose of Betaseron. Mult. Scler. 11 (2005) S112
17. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feicher J., and Ramanathan M. Genomic effects of IFN-β in multiple sclerosis patients. J. Immunol. 171 (2003) 2694-2702
18. Yuryev A., Mulyukov Z., Kotelnikova E., Maslov S., Egorov S., Nikitin A., Daraselia N., and Mazo I. Automatic pathway building in biological association networks. BMC Bioinformatics 7 (2006) 171